Takeda and Protagonist Therapeutics won FDA approval for rusfertide, a new therapy for polycythemia vera branded as Mimrylo. The decision creates a new treatment option for a rare blood disorder that is commonly managed with phlebotomy and cytoreductive strategies, and it provides a regulated entry point for a novel mechanism distinct from traditional approaches. The approval means clinicians can begin prescribing Mimrylo for eligible polycythemia vera patients, bringing a targeted alternative into routine care and supporting Protagonist/Takeda’s development roadmap for additional uses. For the category, the approval also offers an updated signal on payer coverage and clinical adoption patterns for anemia- and thrombocytosis-targeted interventions in myeloproliferative neoplasms.